Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

Regeneron Pharmaceuticals ... The other promising drug is in their growing oncology pipeline, as Zaltrap has given way to Libtayo, their treatment for metastatic melanoma. Libtayo was originally ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other blue chip stocks to invest in at 52-week lows. For the first time since ...

Allow some time for an explanation There are two ways of looking at Regeneron. The sum-of-the-parts way and the platform way. Regeneron has 11 approved drugs but two comprise most of the cash flows.

Long Island's six Regeneron Science Talent Search finalists ... but math gives us a way to translate all the complexity into a language that we can better understand.” Xiao, 17, of Garden ...

For our next session, I'm very excited to have a fireside chat with Regeneron. And it's my pleasure ... hopscotching through the office and smiling in a way that the office staff and physician ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.